JEREMY WINELL: Open Payments
NPI 1598822736 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$730 in 34 payments from 15 companies in 2025. Trend: 2023 $367 · 2024 $699 · 2025 $730
Food & beverage: $730
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $144 |
| Agios Pharmaceuticals, Inc. | 3 | $87 |
| Janssen Biotech, Inc. | 3 | $85 |
| Merck Sharp & Dohme LLC | 4 | $85 |
| Daiichi Sankyo Inc. | 2 | $48 |
| Novartis Pharmaceuticals Corporation | 2 | $45 |
| SERVIER PHARMACEUTICALS LLC | 2 | $39 |
| Syndax Pharmaceuticals, Inc. | 2 | $33 |
| Nuvation Bio Inc. | 1 | $31 |
| Genmab U.S., Inc. | 1 | $28 |
Products named: PYRUKYND, KEYTRUDA, TECVAYLI, NINLARO, Enhertu, Fabhalta, Tibsovo, VPRIV.
Industry payments across NY — which companies pay providers there.
